; GI, gastrointestinal; HMA, hypomethylating agent; HSCT, hematopoietic stem cell transplantation; N/V, nausea and vomiting; R/R, relapse/refractory; TKI, tyrosine kinase inhibitor. Targeting IDH Mutations IDH mutations are found much less frequently
Search Results
Novel and Emerging Treatment Strategies for Acute Myeloid Leukemia
Presented by: Eunice S. Wang
BPI20-019: Pooled Analysis of Phase 3 Studies Comparing a Single-Dose Fixed Combination of Netupitant / Palonosetron (NEPA) vs a 3-Day Aprepitant-Based Regimen (APR) for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC)
Rudolph M. Navari, Erminio Bonizzoni, Rita Wickham, and Rebecca Clark-Snow
2-4. Inclusion/exclusion criteria were similar across studies. Data from the 3 studies were pooled for efficacy endpoints of: 1) complete response (CR: no emesis, no rescue medication); 2) no significant nausea (NSN: max <25 mm on 100 mm VAS); and 3
Antiemesis
David S. Ettinger, Debra K. Armstrong, Sally Barbour, Michael J. Berger, Philip J. Bierman, Bob Bradbury, Georgianna Ellis, Steve Kirkegaard, Dwight D. Kloth, Mark G. Kris, Dean Lim, Michael Anne Markiewicz, Lida Nabati, Carli Nesheiwat, Hope S. Rugo, Steven M. Sorscher, Lisa Stucky-Marshal, Barbara Todaro, and Susan Urba
– 1752 . 5 Morran C Smith DC Anderson DA . Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomized trial of antiemetics . Br Med J 1979 ; 1 : 1323 – 1324 . 6 Jenns K . Importance of nausea
NCCN Guidelines Insights: Antiemesis, Version 2.2017
Michael J. Berger, David S. Ettinger, Jonathan Aston, Sally Barbour, Jason Bergsbaken, Philip J. Bierman, Debra Brandt, Dawn E. Dolan, Georgiana Ellis, Eun Jeong Kim, Steve Kirkegaard, Dwight D. Kloth, Ruth Lagman, Dean Lim, Charles Loprinzi, Cynthia X. Ma, Victoria Maurer, Laura Boehnke Michaud, Lisle M. Nabell, Kim Noonan, Eric Roeland, Hope S. Rugo, Lee S. Schwartzberg, Bridget Scullion, John Timoney, Barbara Todaro, Susan G. Urba, Dorothy A. Shead, and Miranda Hughes
management for any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. Overview Vomiting (emesis) and nausea induced by systemic or radiation therapy (RT) can significantly affect a patient
A Review of the Symptomatic Management of Malignant Gliomas in Adults
Umang Shah and Tara Morrison
brain metastasis undergoing whole-brain radiation suggests possible benefit from the use of memantine. 31 Nausea and Vomiting Chemotherapy-induced nausea and vomiting (CINV) is a frequent problem in oncology patients The primary chemotherapy used
EPR19-74: Risk of Cabozantinib-Associated Gastrointestinal and Hepatic Toxicities in Patients With Metastatic Solid Tumors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Anita Sultan, Sriman Swarup, Francis Mogollon-Duffo, Ye Aung, Yin M. Myat, Myo H. Zaw, Rachana Yendala, Nicholas D’Cunha, and Kyaw Z. Thein
used cabozantinib while the control arm utilized everolimus or placebo or prednisone. The relative risks of all-grade side effects were as follows: diarrhea, 2.495 (95% CI: 2.149–2.897, P <.0001); nausea, 1.849 (95% CI: 1.649–2.072; P <.0001
Prevention of Emesis from Multiple-Day and High-Dose Chemotherapy Regimens
Rudolph M. Navari
current practice in Canada . Supp Cancer Therapy 2005 ; 2 : 181 – 187 . 3. Osoba D Zee B Warr D . Effect of post-chemotherapy nausea and vomiting on health related quality of life . Support Care Cancer 1997 ; 5 : 307 – 313 . 4
Cannabinoids for Symptom Management and Cancer Therapy: The Evidence
Mellar P. Davis
benefits. Marijuana, the dried leaves and flowers of the hemp plant that are smoked as a drug, was on the American pharmacopeia until 1944. It returned in the form of delta(9)-THC (dronabinol) in 1986, approved for treatment of chemotherapy-induced nausea
Phase II Trial of Symptom Screening With Targeted Early Palliative Care for Patients With Advanced Cancer
Camilla Zimmermann, Ashley Pope, Breffni Hannon, Monika K. Krzyzanowska, Gary Rodin, Madeline Li, Doris Howell, Jennifer J. Knox, Natasha B. Leighl, Srikala Sridhar, Amit M. Oza, Rebecca Prince, Stephanie Lheureux, Aaron R. Hansen, Anne Rydall, Brittany Chow, Leonie Herx, Christopher M. Booth, Deborah Dudgeon, Neesha Dhani, Geoffrey Liu, Philippe L. Bedard, Jean Mathews, Nadia Swami, and Lisa W. Le
every outpatient visit using the ESAS-r, with targeted EPC referral according to an algorithm based on symptom severity ( Figure 1 ). The ESAS-r assesses the severity of 9 common cancer symptoms (pain, fatigue, drowsiness, nausea, anxiety, depression
EPR19-73: Risk of Gastrointestinal and Hepatic Toxicities in Patients With Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Treated With CDK4/6 Inhibitors
Anita Sultan, Sriman Swarup, Somedeb Ball, Miguel Quirch, Meily Arevalo, Yin M. Myat, Ye Aung, Myo H. Zaw, and Kyaw Z. Thein
placebo in combination with letrozole or anastrozole or fulvestrant or other hormonal agents. The RR of all-grade side effects were as follows: diarrhea, 1.691 (95% CI: 1.220–2.345; P =.002); nausea, 1.632 (95% CI: 1.447–1.840; P <.001); vomiting, 1
